Correlation Between Serum Procollagen Type 1 N-Terminal Propeptide Level With Modified Rodnan Skin Score In Systemic Sclerosis Patients. by Vincent, Vincent et al.
Original Article
8 Indonesian Journal of Rheumatology 2017; Vol 9 No.2
1 Department of Internal 
Medicine,
2 Division of 
Rheumatology
Faculty of Medicine 
Universitas 
Padjadjaran/ Hasan 
Sadikin General 
Hospital Bandung
Corespondence: 
Vincent, MD
email: vincent.lim.86@ 
gmail.com
Correlation Between Serum Procollagen Type 1 
N-Terminal Propeptide Level With Modified Rodnan Skin 
Score In Systemic Sclerosis Patients.
Vincent1, Sumartini Dewi2 Rachmat Gunadi Wachjudi2
Clinic data revealed some alterations of disease 
patterns prior to JKN (Jaminan Kesehatan Nasional, 
National Health Insurance) enactment in 2014 
compared to the period after the JKN enactment. 
Connective tissue diseases had the largest portion of 
diseases in 2013 and 2014 at Rheumatology Clinic, 
the number rose from 51.2% in 2013 to 63.5% 
in 2014.4,5 Systemic Sclerosis was the third most 
common disease in our Rheumatology Clinic, the 
number of the cases rose from 189 patients/year in 
2013 to 196 patients/year in 2014. Numerous study 
reported that survival rate of the disease has not 
significantly been improved since the last 30 years. 
While the opposite result was reported by some 
other studies, such as Steen, et al study reported 
the increase of 10-year survival rate of systemic 
sclerosis from 53% in 1970s to 67% in 1990s;6 and 
Ehai, et al study revealed the improvement of the 
mortality rate of systemic sclerosis patients for the 
last 40 years.7,8
Modified Rodnan Skin Score (MRSS) is well 
correlated with the gold standard assessment, 
skin biopsy, for skin fibrosis in systemic sclerosis 
disease. However, performing MRSS assesment 
requires great skills. Moreover, even though it is 
well corelated with the gold standard, MRSS is not 
sensitive to detect the small skin alteration happened 
within the development of the disease.1,9 Therefore, 
some biologic markers are necessary used to 
assist clinicians to examine skin fibrosis because 
it is reported more objectively, quantitatively, and 
rapidly in detecting small skin lession in fibrosis 
skin .10 
Procollagen Type-1 Terminal Propeptide 
(P1NP), degraded product from type-1 collagen 
synthesis, is one of the potential biological marker. 
Nevertheless, some studies which has investigated 
the association between skin fibrosis severity 
assessed by MRSS with the level of serum P1NP in 
systemic sclerosis patients, revealed inhomogenous 
results.11,12,13 Further, there is not any study 
examining association between concentration 
of serum P1NP of any disease progressivity, 
particularly skin fibrosis severity according to 
Abstract
Introduction: Systemic Sclerosis (SSc) is a chronic 
autoimmune disease, characterized by vasculopathy, 
specific autoimmune, and fibrosis. Assesment of skin 
fibrosis by modified Rodnan Skin Score (mRSS) can not 
detect the minimal changes of skin fibrosis within less 
than 3 months. A biomarker is needed to assess the 
minimal changes of skin fibrosis progressivity with a 
more objective, quantitative, and rapid way. Procollagen 
type-1 N-Terminal Propeptide (P1NP), a degradation 
product of collagen type-1, may become a potential 
biomarker for skin fibrosis. This study aims to evaluate 
the correlation between skin fibrosis by mRSS with 
P1NP serum in systemic sclerosis.
Methods: This was a cross-sectional study performed 
among systemic sclerosis patients at Rheumatology out-
patient clinic, Dr.Hasan Sadikin Hospital Bandung, from 
May 2016 to July 2016. Skin fibrosis was measured by 
mRSS. P1NP level was determined by ELISA. Data were 
analyzed using Rank-Spearman Correlation.
Result: There were thirty-seven subjects, with mean 
age 37 (SD ±7) years old. Most of subjects were fe-
male (91.9%). Subjects consisted of 23 (62.2%) limited 
SSc and 14 (37.8%) diffuse SSc. Six subjects (16.2%) 
were DMARD naïve. We found median (range) P1NP 
serum was 43.85 (9.81-127.90) ng/dL, while the median 
of MRSS was 14 (3-36). There is a moderate correlation 
between MRSS and P1NP serum (r=0.443, p=0.003)
Conclusion: There was a significant correlation 
between mRSS and P1NP serum in systemic sclerosis 
patient at Dr. Hasan Sadikin Hospital Bandung. 
Keywords: systemic sclerosis, P1NP, modified rodnan 
skin score. 
Introduction
Systemic Sclerosis is an autoimmune disease 
involving many organs with complex 
pathophysiology and heterogenous clinical features. 
The exact etiology of systemic sclerosis remains 
unknown to this day. The disease severity and 
prognosis are varied among the patients, depending 
on the involvement of organs in the disease.1-3
Hasan Sadikin General Hospital Rheumatology 
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MRSS, has ever been conducted in Indonesia. Therefore, the 
study is perform to seek any positive correlation between 
the P1NP level and skin fibrosis severity based on MRSS in 
systemic sclerosis patients. Hopefully P1NP will be able to be 
a biologic marker
Methods
Subject
Subject were chosen from Hasan Sadikin General Hosipital’s 
outpatient clinic and ward who came from may to July 
2016 with consecutive random sampling methods. Samples 
included in this study with criteria: age between 18 to 50 
years old4,14,15 and has been diagnosed as Systemic Sclerosis 
using ACR/EULAR 2013 criteria. Subject were excluded if 
they have some comorbidities, such as osteoporosis16, hepatic 
cirrhosis17, bone metastases malignancy disease18, post 
menopause woman19, and chronic kidney disease20
Subjects were screened for any one of those exclusion 
criteria: osteoporosis, hepatic cirrhosis, bone metastase, 
menopausal status, and chronic kidney disease. Osteoporosis 
were diagnosed if Bone Mineral Densitometry (BMD) T score 
< -2.5, diagnosed as osteoporosis in medical history, or using 
moderate dose steroid therapy (≥ 7,5 mg prednisone/day) 
for more than 3 months with T score <1.5. Hepatic Cirrhosis 
were diagnosed if there is clinical stigmata of chronic 
hepatic disease or diagnosed as cirrhosis in medical records. 
Bone metastasis were assesed by medical record history of 
malignancy and bone metastases. Menopause status reffered 
for this study is when mensturation cycle has been stop for 
12 months or more. Chronic kidney disease reffered for this 
study is when estimated Glomerular Filtration Rate (eGFR) 
< 60 ml/min/1.73m2 counted using The Modification of Diet 
in Renal Disease (MDRD) or has been diagnosed as chronic 
kidney disease in medical records. 
MRSS Examination
MRSS examination were done by selected rheumatology 
consultant. All Hasan Sadikin General Hospital/Padjajaran 
University rheumatology consultants were included for 
“interobserver variability agreement” assesment. Physician 
who has good intraclass correlation coefficient result (>0.7) 
were selected to be the examinee for our study. 
MRSS examination is used to classified skin fibrosis. 
Skin fibrosis were assesed in 17 area of the skin, each area 
will be scored from 0 to 3. Score ‘0’ means normal skin, ‘1’ 
means minimal skin thickening, ‘2’ means moderate skin 
thickening,’3’ means severe skin thickening where the skin 
has been fixated with the deeper tissue. 
P1NP concentration
The concentration of serum P1NP were assesed stimultaneously 
with MRSS examination. Using ELISA sandwich methods. 
The result were served in ng/mL.
Statistical Analysis
Data were analyzed using SPSS version 17.0. Normality of 
the quantitative data were test using Shapiro-Wilk test. We 
used two analysis methods, such as univariate and bivariate 
analysis methods. Pearson correlation test were used to 
assess any correlation in normal distribution data and Rank 
Spearman correlation test were used to assess any correlation 
in not normal distribution data. 
Result
From May to July 2016, we found 40 patients fulfilled the 
inclusion criteria. Three of them were excluded due to 
osteoporosis which is found during the first assesment. 
Within thirty seven subjects, there were 14 subjects (37,8%) 
with diffuse systemic sclerosis and 23 subjects (62,2%) with 
limited systemic sclerosis. Six subjects (16.2%) were newly 
diagnosed systemic sclerosis patients who have never gotten 
methotrexate therapy. The median for disease course were 26 
months, ranged from 6 months to 8 years. 
Table 1. Subject Characteristics
Characteristics Result
Age (years) 37 ± 7 years
Female 34 (91,9%)
Systemic Sclerosis Type
Limited, N(%) 23 (62,2%)
Diffuse, N(%) 14 (37,8%)
Course of Disease (Month) 26 (6 - 96) month
Medication History, N(%) 
Methotrexate 31 (83,8%)
Steroids 27 (73,0%)
Cyclophosphamide 1 (2,7%)
CCB 31 (83,8%)
Aspirins 29 (78,4%)
Clinical Features of ACR EULAR 2013, N(%) 
Finger Fibrosis 37 (100%)
Finger Oedema 24 (64,9%)
Finger Scar 26 (70,3%)
Telangiectasia           13(35,1%)
Salt and Pepper Appearance 21 (56,8%)
Raynaud Phenomenon 33 (89,2%)
MRSS (score) 14 (3 - 31)
CCB: Calcium Channel Blocker
Subjects were diagnosed as sclerosis systemic prior 
to this study. Among the subjects, 31 subjects (83.8%) had 
been treated with methotrexate. Steroids were given to 27 
(73.0%) subjects with equivalent dose less than 7.5 mg of 
prednisone a day (mean 5 mg of prednisone). One subject 
(2.7%) had undergone cyclophosphamide therapy due to lung 
involvement, while calcium channel blockers were given to 
31 (89.2%) subject for treating Raynaud phenomenon.
Finger fibrosis was the most common manifestation, found 
in all subjects, followed by Raynaud phenomenon (33 subjects 
or 89.2% of total subjects), finger ulcers or scars (26 subjects or 
70.3% of total subjects), finger oedema (24 subjects or 64.9% 
of total subjects), salt and pepper appearance (21 subjects or 
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56.8% of total subjects), and telangiectasia (13 subjects or 
35.1% of total subjects).
Table 2 explained the subjects’ laboratory features. All 
hematologic parameter averages were within normal limits. 
This examination was also conducted over the entire subjects 
for detecting any exclusion criteria, such as: hepatic cirrhosis, 
post-menopause, bone-metastasized malignancies, chronic 
kidney disease and osteoporosis.
 
Table 2.  Laboratory Features 
Characteristics (unit) Result
Laboratory features
Hb (g/dL) 12,9 ± 1,2
Leukocytes (/mm3) 8,200 (4,490-19,400)
Trombocytes (/mm3) 312,703 ± 91,743
ESR (mm/h) 28 (6 - 87)
SGOT (U/L) 17 (11 - 59)
SGPT (U/L) 13 (5 - 39)
Creatinine (mg/dL) 0,65±0,15 
Proteinuria, n (%) 0 (0%)
   P1NP (ng/mL) 43,85(9,81-127,90)
 
Bivariate analysis was carried out to test the significancy 
association of P1NP level and MRSS. The result of rank 
spearman correlation test was presented in table 3
Table 3. MRSS Bivariate Test Result of Serum P1NP
Variable  MRSS 
R p-value
P1NP (ng/dL) 0,443 0,003*
NB: Rank spearman analysis was used for analysis, the resilf was 
significant if p <0.05
Bivariate test revealed a significant correlation between 
skin fibrosis severity assessed by MRSS and serum P1NP level 
(p<0.05) as shown in Table 3. The correlation was categorized 
as medium correlation according to Guilford criteria with r 
ranged from 0.40 to 0.70. The scattered diagram of Correlation 
Between MRSS and Serum P1NP is presented in Figure 1.
Figure 1   Scatter Diagram Revealing Correlation 
Between MRSS and Serum P1NP
Discussion
Mean age of subjects involved in this study was 37 ±7 years 
old, explaining that the highest prevalence of systemic 
sclerosis onset was between third and fourth decade.21,22 The 
epidemiology of SSc in our studies is dissimilar with Denton, 
et al study which found the mean age of subjects 48.5 ±11 
years old, but it is consistent with Pagalavan, et al study in 
Malaysia which found the mean age 38.8 years old. The wide 
difference between the two studies might be happened due to 
the different race of the subjects involved. The races difference 
will also contribute to the expression of autoantibody and 
other genetical factors that influence systemic sclerosis 
pathophysiology between Caucasians and Asians.23-25  Female 
constituted for 91.9% of subjects involved in this study. It is 
concordant with the fact that systemic sclerosis mostly affects 
women.21,26 A study was conducted by Low, et al. in Asia also 
revealed 86% of systemic sclerosis patients were women.27
All subjects in this study was diagnosed using first 
criteria, which was skin thickening at fingers of both hands 
that expanded proximally to metacarpophalangeal joints. That 
first criteria was fundamentally similar to major criteria on 
ACR 1980 which means the inclusion criteria of this study 
was similar to the two studies mentioned before. Raynaud 
phenomenon was found in 89.2% of this study’s subjects. 
The phenomenon is, in fact, common at the early stage of 
disease.26,28 Other clinical findings such as finger scars or 
ulcers (70.3% of the subjects) and telangiectasia (35.1% of 
the subjects) was considerably resemble to ones revealed by 
Low, et al., with Raynaud phenomenon, finger scars or ulcers, 
and telangiectasia were found in 80.5%, 70.5%, and 34.5% of 
the subjects, respectively.29
The median for MRSS in this study was 14, ranged 
between 3 to 36. There was a significant difference (p=0.005) 
between the result of MRSS in type diffuse and limited 
systemic sclerosis. As gold standard examination for assessing 
fibrosis severity, MRSS could be helpful in measuring the 
course of disease and skin fibrosis response to therapy. MRSS 
monitoring, based on disease development conducted in a 
longitudinal study, revealed the changing score after 3-6 
month of therapy administration.30-32 The proximal parts of the 
body may return to normal during the therapy, except the part 
which suffered severe fibrosis or atrophy, frequently in the 
distal part of the finger.33
The median level of P1NP serum was 43.85 (9.8-127.90) 
ng/ml. Minier, et al. study showed nearly same result, 45.0 
(34-65) ng/ml.34 The median level of P1NP serum in our study 
was higher than the median level of P1NP serum in non SSc 
patients which presented by Minier, et al study, 33.5 (28.3-
44.5) ng/ml.34 
Bivariate analysis of skin fibrosis assessed by MRSS 
yielded a significant correlation with the level of P1NP 
serum (r=0.443; p=0.003). The result was consider high if we 
compare it to the result revealed by Denton, et al. (r=0.37; 
p=0.027). However both studies show a significant correlation 
(p<0.05) between the two variables.
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Our study supported the fact that P1NP has a role on 
fibrosis process. P1NP is released to the circulation as a 
metabolite in collagen syntesis process, a fundamental process 
of fibrosis.21,35,36 A study conducted by Minier, et al. disclosed 
a significant correlation between MRSS and P1NP compared 
to other biologic markers.37 A study carried out by Denton, et 
al. showed a consistent result with the previous two studies, 
that P1NP does not only have positive correlation with 
MRSS (r=037, p=0.027), but also can be used as marker in 
monitoring the response of therapy.11 P1NP was stated as one 
of the excellent biologic marker for fibrosis process according 
to Panticos, et al. They revealed the presence of excessive 
deposition of type 1 collagen in skin biopsy of systemic 
sclerosis patients.38
We realized some limitation of our study that could 
influence the results of our study.  First, the limitation number 
of the samples due to low prevalence of systemic sclerosis in 
our center. A multicenter study is needed to gather a higher 
number of subjects. Second, the method used in this study 
could not be used to describe the real picture regarding to the 
correlation between P1NP and MRSS.
Conclusion
There was a medium and significant correlation between skin 
fibrosis severity assessed by MRSS and the concentration 
of  P1NP serum in systemic sclerosis patients. Further study 
assessing the correlation between skin fibrosis severity based 
on MRSS and serum P1NP concentration between newly 
diagnosed patients who never got methotrexate and steroid 
using a cohort method are needed in order to reveal the 
correlation of P1NP level in monitoring the therapy response 
and prove the role of P1NP as a potential marker for SSc’s 
disease activity.
The measurement of P1NP serum could be considered as a 
routine examination that would assist clinicians to assess skin 
fibrosis severity in systemic sclerosis patients. 
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